STENA DIAGNOSTICS AKTIEBOLAG

CANAG

IN THE HEADING, INT. CLS.: 1 AND 5 AND PRIOR U.S. CLS.: 6 AND 8 SHOULD BE DELETED AND INT. CL.: 1 AND PRIOR U.S. CL: 6 SHOULD BE INSERTED; AND IN THE STATEMENT, COLUMN 1, LINES 10 AND 11, AND COLUMN 2, LINES 1 THROUGH 4 SHOULD BE DELETED.;RADIOIMMUNOASSAY REAGENTS FOR LABORATORY USE;

CERVAG

DIAGNOSTIC REAGENTS FOR MEDICAL ANALYSIS OF BODY FLUIDS;

COLAG

DIAGNOSTIC REAGENTS FOR MEDICAL ANALYSIS OF BODY FLUIDS AND PHARMACEUTICAL PREPARATIONS TO TREAT CANCER IN HUMANS;

LUNGAG

PHARMACEUTICAL PREPARATIONS TO TREAT CANCER IN HUMANS;RADIOIMMUNOASSAY REAGENTS FOR LABORATORY USE FOR DIAGNOSIS OF CANCER IN HUMANS;MEDICAL TEST KIT FOR THE EARLY DETECTION OF CANCER IN HUMANS CONTAINING MONOCLONAL ANTIBODIES FOR USE IN HOSPITALS OR DOCTORS OFFICES;

MAMAG

PHARMACEUTICAL PREPARATIONS TO TREAT CANCER IN HUMANS;RADIOIMMUNOASSAY REAGENTS FOR LABORATORY USE FOR DIAGNOSIS OF CANCER IN HUMANS;MEDICAL TEST KIT FOR THE EARLY DETECTION OF CANCER IN HUMANS CONTAINING MONOCLONAL ANTIBODIES FOR USE IN HOSPITALS OR DOCTORS OFFICES;

MELAG

CHEMICAL REAGENTS FOR DIAGNOSTIC ANALYSIS OF BODY FLUIDS; PHARMACEUTICAL PREPARATIONS FOR TREATMENT OF CANCER DISEASES;

OVAG

RADIOIMMUNOASSAY REAGENTS FOR MEDICAL DIAGNOSTIC USE IN DETECTING CANCER IN HUMANS; AND PHARMACEUTICAL PREPARATIONS TO TREAT CANCER IN HUMANS;

PANAG

PHARMACEUTICAL PREPARATIONS TO TREAT CANCER IN HUMANS;RADIOIMMUNOASSAY REAGENTS FOR LABORATORY USE FOR DIAGNOSIS OF CANCER IN HUMANS;MEDICAL TEST KIT FOR THE EARLY DETECTION OF CANCER IN HUMANS CONTAINING MONOCLONAL ANTIBODIES FOR USE IN HOSPITALS OR DOCTORS OFFICES;

SPINAG

PHARMACEUTICAL PREPARATIONS TO TREAT CANCER IN HUMANS;RADIOIMMUNOASSAY REAGENTS FOR LABORATORY USE FOR DIAGNOSIS OF CANCER IN HUMANS;MEDICAL TEST KIT FOR THE EARLY DETECTION OF CANCER IN HUMANS CONTAINING MONOCLONAL ANTIBODIES FOR USE IN HOSPITALS OR DOCTORS OFFICES;

SQUEMAG

PHARMACEUTICAL PREPARATIONS TO TREAT CANCER IN HUMANS;RADIOIMMUNOASSAY REAGENTS FOR LABORATORY USE FOR DIAGNOSIS OF CANCER IN HUMANS;MEDICAL TEST KIT FOR THE EARLY DETECTION OF CANCER IN HUMANS CONTAINING MONOCLONAL ANTIBODIES FOR USE IN HOSPITALS OR DOCTORS OFFICES;

STENA DIAGNOSTICS

IN THE HEADING, INT. CLS.: 1 AND 5 ANDPRIOR U.S. CLS.: 6 AND 18 SHOULD BE DELETED AND INT. CL.: 1; PRIOR U.S. CL.: 6 SHOULD BE INSERTED; AND IN THE STATEMENT, COLUMN 1, LINES 10 THROUGH 13 SHOULD BE DELETED AND COLUMN 2, LINES 1 AND 2SHOULD BE DELETED; AND COLUMN 2, BEFORE LINE 3, PRIORITY CLAIMED UNDER SEC. 44 (D) ON SWEDEN APPLICATION NO. 84-4751, FILED 6-20-1984. SHOULD BE INSERTED.;RADIOIMMUNOASSAY REAGENTS FOR LABORATORY USE;DIAGNOSTICS;THE MARK IS LINED FOR THE COLORS RED, YELLOW, GREEN, AND BLUE AND COLOR IS CLAIMED AS A FEATURE OF THE MARK.;

STENA DIAGNOSTICS

PHARMACEUTICAL AND VETERINARY PREPARATIONS FOR USE WITH IN VIVO DIAGNOSTICS AND THERAPY;DIAGNOSTICS;THE DRAWING IS LINED FOR THE COLORS RED, YELLOW, GREEN, AND BLUE, AND COLOR IS CLAIMED AS A FEATURE OF THE MARK.;

STOMAG

PHARMACEUTICAL PREPARATIONS TO TREAT CANCER IN HUMANS;RADIOIMMUNOASSAY REAGENTS FOR LABORATORY USE FOR DIAGNOSIS OF CANCER IN HUMANS;MEDICAL TEST KIT FOR THE EARLY DETECTION OF CANCER IN HUMANS CONTAINING MONOCLONAL ANTIBODIES FOR USE IN HOSPITALS OR DOCTORS OFFICES;